Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

AstraZeneca Launches Trastuzumab deruxtecan in India for HER2-Positive Breast Cancer

NextEdge Admin

04 Dec 2023

2 min 40 sec

On Wednesday, AstraZeneca announced the launch of Trastuzumab deruxtecan, a groundbreaking therapy for adult patients grappling with unresectable or metastatic HER2-positive breast cancer, developed in collaboration with Daiichi Sankyo. This engineered HER2-directed antibody-drug conjugate (ADC) stands as a beacon of hope for those who have previously undergone anti-HER2 regimens.

Breast cancer, identified by the World Health Organization as the most diagnosed cancer globally, has seen a 40% surge in incidence in India over the past 25 years. Trastuzumab deruxtecan addresses this critical medical need, offering a targeted approach by specifically binding to HER2 receptors and delivering a cytotoxic payload directly to cancer cells.

Dr. Meenu Walia, Vice Chairman-Medical Oncology at Max Super Speciality Hospital, hailed Trastuzumab deruxtecan as a significant advancement in HER2-positive breast cancer treatment, emphasizing its efficacy and breakthrough clinical outcomes observed globally. The therapy’s introduction is supported by positive results from the global Phase III DESTINY-Breast03 trial.

Dr. Anil Kukreja, Vice-President, Medical Affairs and Regulatory at AstraZeneca India, underscored the urgent need to provide transformative medicine to patients with HER-2 positive metastatic breast cancer who have already progressed on initial anti-HER2 targeted treatment. He expressed AstraZeneca’s commitment to redefining cancer care and eradicating cancer as a cause of death.

Trastuzumab deruxtecan, representing a significant stride in the fight against breast cancer, demonstrated a 72% reduction in the risk of disease progression or death compared to trastuzumab emtansine (T-DM1) in primary results published in The New England Journal of Medicine. Import and marketing approval from the Drug Controller General of India in May 2023 adds to the optimism surrounding this transformative therapy.